Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 33 n° 335

Posts Tagged ‘immuno-oncology’

Collaboration Aims to Discover New Immuno-oncology Targets

Posted by fidest press agency su mercoledì, 14 agosto 2019

Harvard University and Merck are launching a collaboration that will provide significant research funding for up to four years to support immuno-oncology research led by Arlene Sharpe, MD, PhD, at Harvard Medical School (HMS). Sharpe, the George Fabyan Professor of Comparative Pathology and chair of the HMS Department of Immunology, will collaborate with researchers at Merck on a major project aiming to discover novel aspects of the immune system that may be targeted in future treatments for cancer.“This collaborative project aims to discover and validate novel regulators of immune responses,” said Dr. Sharpe. “Immunotherapies such as checkpoint inhibitors have revolutionized the treatment of cancer, but my lab is deeply interested in understanding why some patients do not respond or develop resistance to those interventions. My hope is that by defining mechanisms that inhibit immune responses to tumors, we will identify very important druggable targets and new approaches to improve cancer immunotherapy.”The funding will support the work of scientists in the lab of Dr. Sharpe, who is a renowned leader in the field of tumor immunology. She is a member of the National Academy of Sciences and the National Academy of Medicine, and the recipient of numerous awards including the Warren Alpert Foundation Prize in 2017 for her contributions to the discovery of the PD-1 pathway.Under the agreement spearheaded by Harvard’s Office of Technology Development, Merck will have the option to negotiate an exclusive license to innovations arising from the research collaboration to develop these discoveries toward potential treatments for patients.“Collaboration with leading scientific groups is an integral part of Merck’s discovery strategy,” said Dr. Nick Haining, vice president for oncology discovery at Merck Research Laboratories. “We look forward to working with Dr. Sharpe’s team to investigate new ways to harness the immune system for therapeutic advances.”

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

5th Annual Immuno-oncology BD&L and Investment Forum

Posted by fidest press agency su domenica, 26 Maggio 2019

Chicago, Illinois Friday, May 31, 2019 10:30 AM Waldorf Astoria Chicago Hotel, immunomic Therapeutics, Inc. (ITI), a privately held, Maryland-based biotechnology company, announced that the company will present at the 5th Annual Immuno-oncology BD&L and Investment Forum. Sia Anagnostou, Immunomic’s Senior Director of Corporate Development, will present a company overview and will discuss ITI’s recently expanded, investigational UNiversal Intracellular Targeted Expression (UNITE) platform and its application in immuno-oncology, specifically glioblastoma multiforme (GBM). ITI’s technology platform has the potential to utilize the body’s natural biochemistry to develop a broad immune response and is currently being employed in a Phase II clinical trial as a cancer immunotherapy.

Posted in Estero/world news | Contrassegnato da tag: , | Leave a Comment »

Kyn Therapeutics Enters into Global Strategic Collaboration with Celgene to Develop Immuno-oncology Therapies

Posted by fidest press agency su lunedì, 21 gennaio 2019

Kyn Therapeutics, a clinical-stage biotechnology company advancing research into new immunometabolic therapies for treating cancer, today announced it has entered into a global strategic collaboration with Celgene Corporation (NASDAQ:CELG). The goal of the collaboration is to develop novel immuno-oncology therapies through uniting Kyn’s immuno-oncology expertise and pipeline with Celgene’s capabilities for developing and commercializing medicines in areas of high unmet medical need. The collaboration begins with an upfront payment and an equity investment by Celgene, which receives exclusive options to license Kyn’s aryl hydrocarbon receptor (AHR) antagonist program and its kynurenine-degrading enzyme (“Kynase”) program.AHR and kynurenine are associated with immunosuppression in a range of tumor types through multiple cellular metabolic mechanisms that modulate both innate and adaptive immunity. These attributes make them compelling targets for investigative therapies, in particular in patients who do not fully benefit from current treatments like checkpoint inhibitors.
“This collaboration signals our continued commitment to work with partners to develop innovative treatments for patients with unmet medical need,” said Robert Hershberg, M.D., Ph.D., EVP, head of business development and global alliances for Celgene Corporation.
Under the terms of the agreement, Kyn will receive an upfront cash payment of $80 million and an equity investment from Celgene for exclusive options to globally license the Kynase and AHR antagonist programs. For each program, Kyn is responsible for R&D activities through Phase 1b, at which time Celgene can opt in to lead and fund global development and commercialization of the licensed programs. If successful, Kyn is eligible for substantial clinical, regulatory and commercial milestone payments. Kyn will also receive tiered royalties on worldwide net sales on products resulting from development of the licensed programs.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Five Prime Presents on Novel B7-H4 Therapeutic Antibody at the 2018 AACR Annual Meeting

Posted by fidest press agency su giovedì, 19 aprile 2018

Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, announced that an oral presentation featuring FPA150, Five Prime’s first-in-class B7-H4 antibody, was given today at the 2018 AACR Annual Meeting in Chicago. The presentation titled “FPA150: A Recombinant, Afucosylated, Fully Human IgG1 Monoclonal Antibody for the Treatment of Malignancies that Express High Levels of B7-H4” by Charles Kaplan is available at FPA150 is a novel B7-H4 antibody that possesses both T cell immune checkpoint blockade and antibody-dependent cellular cytotoxicity (ADCC) activities. FPA150 demonstrates dose-dependent anti-tumor activity in vivo as a monotherapy and elicits complete tumor regressions in preclinical tumor models when given in combination with PD-1 blockade. Five Prime is currently studying FPA150 in a Phase 1 monotherapy trial in patients with solid tumors that overexpress B7-H4.“Our monoclonal B7-H4 antibody, FPA150, appears to possess both T cell checkpoint blockade activity and enhanced ADCC,” said Bryan Irving, Ph.D., Senior Vice President of Research, at Five Prime. “We are studying FPA150 in patients whose tumors overexpress B7-H4 and in which there is high unmet need for immuno-oncology treatments, such as in breast, ovarian and endometrial cancer. Based on the therapeutic properties of FPA150, we believe that this agent has the potential to be an effective therapeutic by improving anti-tumor immune responses in cancer patients.” B7-H4 is a member of the B7-family of T cell immune checkpoint ligands and shares significant homology with other family members, including PD-L1 and PD-L2. B7-H4 is expressed in several human tumors such as carcinomas of the bladder, breast, ovary and endometrium, and its expression tends to correlate with poor prognosis. B7-H4 is also a documented T cell immune checkpoint inhibitory ligand capable of directly suppressing T cell responses.In Investigational New Drug (IND)-enabling pharmacokinetics (PK) and toxicity studies, FPA150 demonstrated a suitable PK profile and was generally well tolerated. A B7-H4 immunohistochemistry (IHC) assay is in development for clinical use as a companion diagnostic to help identify the patients who might benefit most from this treatment.Five Prime is studying FPA150 in a Phase 1 monotherapy trial with a dose-escalation phase in patients with solid tumors, followed by dose expansion in pre-specified cohorts in tumor types based on B7-H4 expression levels. The initial targeted tumors are advanced or metastatic breast, ovarian, endometrial and bladder cancers.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »